Loading
Igg4 Related and Inflammatory Diseases / Autoimmune Neurological Disorders and Treatments · Review
Movement Disorders Clinical Practice · August 14, 2026
Encouraging direction, but not yet definitive.
This systematic review and pooled case analysis of 64 anti-amphiphysin SPSD cases identifies a stiffness hierarchy (lower limbs most common), strong association with malignancy (93.8%), and good functional outcomes (56.8%) particularly with combined symptomatic, immunomodulatory, and oncological therapy (65.5%) or oncological remission (76.9%). The evidence is observational and retrospective, making it suitable for characterizing disease presentation and outcome patterns but not for establishing causality or treatment efficacy.
Systematic review with pooled retrospective case series analysis. Published case reports and case series of anti-amphiphysin SPSD; two additional Asian cases (Chinese Malaysian and Indian) presented; cases predominantly associated with malignancy. Intervention: Varied: symptomatic therapy, intravenous immunoglobulin (IVIG), tumor resection, combined 'triple' therapy (symptomatic + immunomodulatory + oncological). Compared with: Outcomes stratified by treatment approach but no explicit control group; comparisons are between subgroups receiving different treatments or achieving different oncological outcomes. n = 64. Not systematically specified; cases drawn from literature review (international) plus two new Asian cases; geographic diversity noted as limited prior Asian reports.
Lower limbs affected in 82.2% (37/45), upper limbs in 57.8%, paraspinal muscles in 55.6% of cases Malignancy occurred in 93.8% (60/64), with breast cancer predominating at 73.4% (47/64) and lung at 14.1% (9/64) SPSD symptoms preceded cancer detection in 80.0% (32/40) by median of 8 months (range 1–60)
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians should maintain high diagnostic suspicion for anti-amphiphysin SPSD, particularly in patients with atypical presentations such as isolated upper-limb stiffness. Early tumor detection and combined symptomatic-immunomodulatory-oncological management are associated with better functional outcomes; oncological remission appears critical to prognosis.
A systematic review with pooled case series analysis (n=64) describing clinical features, outcomes, and treatment responses in anti-amphiphysin SPSD, but lacking a comparator group and relying on retrospective heterogeneous case data without controlled design.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians should maintain high diagnostic suspicion for anti-amphiphysin SPSD, particularly in patients with atypical presentations such as isolated upper-limb stiffness. Early tumor detection and combined symptomatic-immunomodulatory-oncological management are associated with better functional outcomes; oncological remission appears critical to prognosis.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Abstract Background Anti‐amphiphysin stiff‐person spectrum disorders (SPSD) are paraneoplastic syndromes with few Asian reports and limited clinico‐demographic data. We present two Asian cases alongside the largest pooled cohort analysis to date ( n = 64). Cases Two breast adenocarcinoma‐associated cases are presented. Case 1 (Chinese Malaysian) describes an unusual upper‐limb stiff‐limb syndrome (SLS) resolving fully following early tumor resection and intravenous immunoglobulin (IVIG). Case 2 (India) describes stiff‐person syndrome (SPS) with relief from IVIG, but died from cancer progression. Literature Review Analysis of 64 cases of anti‐amphiphysin SPSD revealed a stiffness hierarchy: lower limbs (37/45 = 82.2%) were most frequently affected, followed by upper limbs (57.8%), paraspinal muscles (55.6%), neck (28.9%), abdomen (26.7%), thorax (8.9%), and face (2.2%). Malignancy occurred in 93.8% ( n = 60/64), the majority involving breast (73.4%, n = 47/64) or lung (14.1%, n = 9/64). SPSD symptoms preceded cancer detection in 80.0% ( n = 32/40) by a median of 8 (range:1–60) months. Overall, the majority of cases (25/44 = 56.8%) had good functional outcomes (modified Rankin Scale ≤2). Good outcomes were documented in most (19/29 = 65.5%) patients receiving “triple” (symptomatic, immunomodulatory, oncological) therapy and those with oncological remission reported (10/13 = 76.9%). Conclusions Properly managed, anti‐amphiphysin SPSD has good outcomes in the majority of patients, particularly when the underlying cancer is successfully treated. Atypical presentations, including upper‐limb SLS, warrant high diagnostic suspicion.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.